SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-22-052937
Filing Date
2022-04-29
Accepted
2022-04-29 08:45:46
Documents
6
Period of Report
2022-06-15

Document Format Files

Seq Description Document Type Size
1 DEF 14A tm2213667-1_def14a.htm DEF 14A 444906
2 GRAPHIC lg_checkpointthera-4c.jpg GRAPHIC 102215
3 GRAPHIC sg_jamesfoliviero-bw.jpg GRAPHIC 5539
4 GRAPHIC sg_garrettgray-bw.jpg GRAPHIC 5587
5 GRAPHIC tm2219667d1-px_scanbw.jpg GRAPHIC 422542
6 GRAPHIC tm2219667d1-px_checkbw.jpg GRAPHIC 548178
  Complete submission text file 0001104659-22-052937.txt   1931740
Mailing Address 2 GANSEVOORT STREET 9TH FLOOR NEW YORK NY 10014
Business Address 2 GANSEVOORT STREET 9TH FLOOR NEW YORK NY 10014 212-554-4366
Checkpoint Therapeutics, Inc. (Filer) CIK: 0001651407 (see all company filings)

IRS No.: 472568632 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38128 | Film No.: 22870525
SIC: 2834 Pharmaceutical Preparations